News >

Emerging Findings Offer Hope With Less Common Genomic Drivers of Lung Cancer

Angelica Welch
Published: Monday, Apr 23, 2018

Dr Alexander Drilon

Alexander Drilon, MD
Non–small cell lung cancer (NSCLC) is highly enriched for genomic drivers, and many are clinically actionable. Targeted therapies are currently available in the clinic to treat patients who harbor these mutations, with several that are FDA approved and more that are incorporated into the NCCN guidelines. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication